BR112015014391B1 - compostos antimicrobianos, seus métodos de preparação, composição e sal farmaceuticamente aceitável dos mesmos - Google Patents

compostos antimicrobianos, seus métodos de preparação, composição e sal farmaceuticamente aceitável dos mesmos Download PDF

Info

Publication number
BR112015014391B1
BR112015014391B1 BR112015014391-1A BR112015014391A BR112015014391B1 BR 112015014391 B1 BR112015014391 B1 BR 112015014391B1 BR 112015014391 A BR112015014391 A BR 112015014391A BR 112015014391 B1 BR112015014391 B1 BR 112015014391B1
Authority
BR
Brazil
Prior art keywords
lys
boc
str
group
compound
Prior art date
Application number
BR112015014391-1A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015014391A2 (pt
Inventor
Jayanta Haldar
Chandradhish Ghosh
Goutham Belagula Manjunath
Padma Akkapeddi
Original Assignee
The Secretary Of State For Health
Jawaharlal Nehru Centre For Advanced Scientific Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Secretary Of State For Health, Jawaharlal Nehru Centre For Advanced Scientific Research filed Critical The Secretary Of State For Health
Publication of BR112015014391A2 publication Critical patent/BR112015014391A2/pt
Publication of BR112015014391B1 publication Critical patent/BR112015014391B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/12Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112015014391-1A 2012-12-18 2013-12-18 compostos antimicrobianos, seus métodos de preparação, composição e sal farmaceuticamente aceitável dos mesmos BR112015014391B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN5299/CHE/2012 2012-12-18
IN5299CH2012 2012-12-18
PCT/IB2013/061090 WO2014097178A1 (en) 2012-12-18 2013-12-18 Antimicrobial compounds, their synthesis and applications thereof

Publications (2)

Publication Number Publication Date
BR112015014391A2 BR112015014391A2 (pt) 2017-07-11
BR112015014391B1 true BR112015014391B1 (pt) 2020-11-03

Family

ID=54148251

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015014391-1A BR112015014391B1 (pt) 2012-12-18 2013-12-18 compostos antimicrobianos, seus métodos de preparação, composição e sal farmaceuticamente aceitável dos mesmos

Country Status (9)

Country Link
US (1) US9783490B2 (https=)
EP (1) EP2934563B1 (https=)
JP (1) JP6533466B2 (https=)
CN (1) CN104981249B (https=)
AU (1) AU2013365769B2 (https=)
BR (1) BR112015014391B1 (https=)
CA (1) CA2894202A1 (https=)
HK (1) HK1210437A1 (https=)
WO (1) WO2014097178A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105566149B (zh) * 2016-03-02 2017-05-24 郑州大学 具有抗菌活性的查尔酮阳离子抗菌肽模拟物及其制备方法
CN106995384B (zh) * 2017-04-21 2018-12-11 郑州大学 具有抗菌活性的二烷基阳离子两亲性抗菌肽模拟物及其制备方法
US20200354413A1 (en) 2017-12-15 2020-11-12 Dana-Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59309867D1 (de) 1992-09-03 1999-12-16 Boehringer Ingelheim Pharma Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
US5654451B1 (en) * 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
AU1441195A (en) * 1993-12-30 1995-07-17 Smithkline Beecham Corporation Phenylmethyl hexanamides, and the use thereof
US5663148A (en) 1994-07-12 1997-09-02 Abbott Laboratories Anaphylatoxin receptor ligands containing lipophilic residues
US6071890A (en) * 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
DE69612962T2 (de) * 1995-12-12 2001-11-15 Taiho Pharmaceutical Co. Ltd., Tokio/Tokyo Epoxysuccinamid-derivate oder deren salze und medikamente die diese enthalten
CA2217550A1 (en) * 1996-10-22 1998-04-22 F. Hoffmann-La Roche Ag Cationic lipids for gene therapy
BR9813554A (pt) * 1997-12-12 2001-07-24 Fuji Yakuhin Kogyo Kk Composto, uso do mesmo, processo para produzi-lo, composição farmacêutica ou veterinária, e, inibidor de metaloproteinase
WO2001040198A2 (fr) * 1999-11-30 2001-06-07 Aventis Pharma S.A. Derives macrocycliques de l'acide hydroxamique et leur utilisation en tant qu'antimicrobiens
JP2002161084A (ja) * 2000-11-28 2002-06-04 Sumitomo Pharmaceut Co Ltd 複素環誘導体
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
GB0512751D0 (en) * 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
US8097582B2 (en) 2006-05-09 2012-01-17 Neobiotics Ab Peptide derivatives useful as antimicrobial agents and for treating wounds
AU2007304847A1 (en) * 2006-10-04 2008-04-10 Inimex Pharmaceuticals, Inc. Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
EP2091917A1 (en) * 2006-12-11 2009-08-26 Wyeth a Corporation of the State of Delaware Ion channel modulators
CN102757477B (zh) * 2011-04-27 2014-09-03 首都医科大学 烯丙基半胱氨酰氨基酸甲酯衍生物及其合成方法和应用
EP2709619B1 (en) * 2011-05-16 2017-10-11 Cellceutix Corporation Compounds for use in treatment of mucositis

Also Published As

Publication number Publication date
US9783490B2 (en) 2017-10-10
AU2013365769B2 (en) 2018-03-15
CA2894202A1 (en) 2014-06-26
CN104981249B (zh) 2018-06-19
JP6533466B2 (ja) 2019-06-19
US20150329478A1 (en) 2015-11-19
EP2934563A1 (en) 2015-10-28
EP2934563B1 (en) 2020-07-08
BR112015014391A2 (pt) 2017-07-11
WO2014097178A1 (en) 2014-06-26
CN104981249A (zh) 2015-10-14
AU2013365769A1 (en) 2015-07-02
JP2016504330A (ja) 2016-02-12
HK1210437A1 (en) 2016-04-22
EP2934563A4 (en) 2016-08-17

Similar Documents

Publication Publication Date Title
Konai et al. Membrane active phenylalanine conjugated lipophilic norspermidine derivatives with selective antibacterial activity
Ghosh et al. Small molecular antibacterial peptoid mimics: the simpler the better!
AU2001268512A1 (en) Chemically-modified peptides, compositions, and methods of production and use
DE102007036128A1 (de) Antibiotische Peptide
CN103435686B (zh) 抗耐药性细菌感染多肽Cbf-14及其用途
BR112016030580B1 (pt) Polipeptídeo de lisina e fragmento de polipeptídeo com atividade para matar bactérias gram-negativas
Yang et al. Antibacterial and antibiofilm formation activities of pyridinium-based cationic pillar [5] arene against Pseudomonas aeruginosa
US11059860B2 (en) Biocidal peptide and preparation based thereon
BR112021009746A2 (pt) Composição para injeção e método de preparo da mesma
CN118638188B (zh) 数据库辅助设计靶向大肠杆菌抗菌肽及其制备方法和应用
BR112015014391B1 (pt) compostos antimicrobianos, seus métodos de preparação, composição e sal farmaceuticamente aceitável dos mesmos
US20110152175A1 (en) Dendrimeric compounds comprising amino acids, hyperbranched core compound, process for preparation of dendrimeric compounds comprising amino acids and hyperbranched core compound, and use thereof
CN104292301A (zh) 一种小分子合成抗菌肽及其制备方法与应用
CN102391362B (zh) 一组动物源性阳离子抗菌肽及其应用
CN102827288A (zh) 一种酸激活csp靶向抗菌肽及其制备和应用
US20170218024A1 (en) Low substituted polymyxins and compositions thereof
CN114989246B (zh) Fk3多肽类似物及其应用
CN117138024B (zh) 一种万古霉素-抗菌肽偶合物及其应用
WO2023066980A1 (de) 4-aminophenylphosphorylcholin-verbindungen zur blockade von c-reaktivem protein
CN121574193A (zh) 基于fk3的碳硼烷偶联肽及其制备方法和应用
Sheyi et al. Self‐Assembly of Branching and Linear Synthetic Polycationic Peptides in Phosphate Buffer and Its Impact on Antimicrobial Activity
Ghosh Development of L-Lysine-based small molecules as broad-spectrum antimicrobial agents
CN104356202A (zh) 一种阳离子抗菌肽及其制备方法与应用
CN110818684A (zh) 一种抗金黄色葡萄球菌毒力和生物被膜形成的抑制剂Lo-SH及其用途
CN110818685A (zh) 一种抗金黄色葡萄球菌毒力和生物被膜形成的抑制剂Lo-异己基及其用途

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 8A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2649 DE 13-10-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.